News Conference News ACC 2019 REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events Yael L. Maxwell March 22, 2019
News Conference News ISC 2019 Cilostazol-Based DAPT Safe, Effective in Patients at High Risk for Recurrent Stroke Todd Neale February 12, 2019
News Conference News VIVA 2018 Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease L.A. McKeown November 15, 2018
News Conference News TCT 2018 More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses Michael O'Riordan September 24, 2018
News Conference News TCT 2018 OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients Todd Neale September 24, 2018
News Conference News ESC 2018 GLOBAL LEADERS: Ticagrelor Monotherapy Fails to Beat Conventional DAPT After PCI Michael O'Riordan August 27, 2018
News Daily News ADAPT-DES: High On-Aspirin Platelet Reactivity Not Related to PCI Outcomes Todd Neale August 17, 2018
News Daily News TRIUMPH in Print: Triple-Drug Polypill Shines for Fast, Safe Blood Pressure Reduction Shelley Wood August 15, 2018
News Daily News Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51 Michael O'Riordan July 06, 2018
News Daily News New Review Probes Possibility of CVD Prevention Without Aspirin Michael O'Riordan July 04, 2018
News Daily News To Cut CV Risk in Diabetes, Prescribe the Right Meds and Push for Lifestyle Changes Michael O'Riordan April 17, 2018
News Features ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging Michael O'Riordan March 23, 2018
News Conference News ACC 2018 High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab Michael O'Riordan March 20, 2018
News Conference News ACC 2018 Low-Dose, Three-Drug Polypill TRIUMPHs for Blood Pressure Shelley Wood March 12, 2018
News Conference News CRT 2018 Ticagrelor: Better Platelet Blockade Post-TAVR? Michael O'Riordan March 07, 2018
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018
News Conference News AHA 2017 Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear Todd Neale November 14, 2017
News Daily News Lp(a) Not Associated With Adverse Cardiovascular Events in ACS Patients Michael O'Riordan October 26, 2017
News Features COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict Todd Neale September 15, 2017